ADVERTISEMENT

Shorter Combo Therapy Effective for Latent TB

Author and Disclosure Information

FROM AN INTERNATIONAL CONFERENCE OF THE AMERICAN THORACIC SOCIETY

"As someone who has been in the business of fighting TB for a long time, I can’t tell you how pleased I am to be able to offer a 3-month regimen: 12 doses and you are done," Dr. Castro said in a telebriefing May 16. Practitioners are always struggling to get patients to complete a 9-month regimen for TB, but with limited success, he said.

"This provides a fantastic opportunity to have the desired impact as a preventive therapy regimen [for TB]," Dr. Castro said.

Dr. Sterling reported that he had no relevant conflicts of interest. Sanofi-Aventis, manufacturer of rifapentine, provided the drug for the trial. Dr. Castro also had no relevant conflicts of interest.